



| Catalog No. | HS925010 |
|---|---|
| Description |
InVivoMAb Anti-Human RAGE/AGER Antibody (7F9) [7F9] (HS925010) is a mouse monoclonal antibody detecting Advanced glycosylation end product-specific receptor in ELISA, FuncS. Suitable for Human.
|
| Species reactivity | Human |
| Applications | ELISA, FuncS |
| Host species | Mouse |
| Isotype | IgG2a, kappa |
| Clone ID | 7F9 |
| Clonality | Monoclonal |
| Target | Advanced glycosylation end product-specific receptor, Receptor for advanced glycosylation end products, AGER, RAGE |
| Endotoxin level | Please contact with the lab for this information. |
| Purity | >95% as determined by SDS-PAGE. |
| Purification | Protein A/G purified from cell culture supernatant. |
| Accession | Q15109 |
| Form | Liquid |
| Storage buffer | 0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Background | Advanced glycosylation end product-specific receptor (RAGE/AGER) is a ~42 kDa protein. Cell surface pattern recognition receptor that senses endogenous stress signals with a broad ligand repertoire including advanced glycation end products, S100 proteins, high-mobility group box 1 protein/HMGB1, amyloid beta/APP oligomers, nucleic acids, histones, phospholipids and glycosaminoglycans. Advanced glycosylation end products are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes. These ligands accumulate at inflammatory sites during the pathogenesis of various diseases including diabetes, vascular complications, neurodegenerative disorders and cancers, and RAGE transduces their binding into pro-inflammatory responses. Upon ligand binding, uses TIRAP and MYD88 as adapters to transduce the signal ultimately leading to the induction of inflammatory cytokines IL6, IL8 and TNFalpha through activation of NF-kappa-B. Interaction with S100A12 on endothelium, mononuclear phagocytes, and lymphocytes triggers cellular activation, with generation of key pro-inflammatory mediators. 1. Shang, D. et al. (2016) Scientific reports 6, 32180. PMID: 27572515 2. Evankovich, J. et al. (2017) FASEB journal : official publication of the Federation of American Societies for Experimental Biology 31, 3894-3903. PMID: 28515150 3. Wang, G. et al. (2021) Cell death discovery 7, 337. PMID: 34743181 4. Yang, Y. et al. (2022) Communications biology 5, 824. PMID: 35974093 5. Sirois, CM. et al. (2013) The Journal of experimental medicine 210, 2447-63. PMID: 24081950 6. Xue, J. et al. (2011) Structure (London, England : 1993) 19, 722-32. PMID: 21565706 7. Sakaguchi, M. et al. (2011) PloS one 6, e23132. PMID: 21829704 8. Yan, Z. et al. (2021) Nature communications 12, 308. PMID: 33436632 9. Moroz, OV. et al. (2009) BMC biochemistry 10, 11. PMID: 19386136 10. Fang, F. et al. (2010) FASEB journal : official publication of the Federation of American Societies for Experimental Biology 24, 1043-55. PMID: 19906677 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |

SDS-PAGE for InVivoMAb Anti-Human RAGE/AGER Antibody (7F9)

Detects recombinant RAGE (Catalog No: HS925021) in indirect ELISA.




Contact us for custom quotes, bulk requests and any other issues.
Mail: support@abinScience.com




+86-27-87433958
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский